最新刊期
卷 27 ， 期 12 ， 2017
-
-
-
- 摘要：Background and purpose: Piwil2 is highly expressed in precancerous and cancer stem cells, which plays a key role in the process of tumorigenesis and progression through the transcriptional and post-transcriptional regulation of gene expression. This study aimed to elucidate the role of Piwil2 in regulating the malignant process of cervical cancer. Methods: In order to generate cell line with overexpression or silence of Piwil2, HeLa and SiHa cells were transfected with lentiviral pLenti-CMV-Piwil2-SV40-EGFP or plasmid shPiwil2, respectively. Cell proliferation assays using CCK-8 were performed in 96-well format in duplicate. Cell cycle and side population (SP) cells were analyzed by fluorescence-activated cell sorting (FACS). The proteins related to cell growth and cell cycle were measured by Western blot. CCK-8 assay was also used to assess the killing effects of cisplatin. Results: Overexpression of Piwil2 promoted cervical cancer cell proliferation and the entry of cells from G0/G1 phase into S phase, as compared to the control cells (P<0.05). On the contrary, Piwil2 knockdown suppressed proliferation of both cells and increased the number of cells during G0/G1 phase markedly (P<0.05). Western blot analyses confirmed that Piwil2 overexpression led to an upregulation of cyclin D1 and p-Stat3 but a significantly decreased level of p53. Furthermore, overexpression of Piwil2 significantly increased the SP cell populations in both HeLa and SiHa cells (P<0.01), sequentially enhanced resistance in cancer cells to cisplatin (P<0.01). Instead, Piwil2 gene knockdown induced an apparent downregulation of cyclin D1 and p-Stat3, significantly increased p53 expression, and decreased proportion of SP cells, which, to some extent, contributed to the improved sensitivity to cisplatin. Conclusion: Piwil2 plays an essential role in the progression of cervical cancer via increasing the proportion of SP cells. Therefore, targeting Piwil2 may be an effective therapeutic option for patients with cervical cancer.关键词：Piwil2;Cervical cancer;Side population cells;Drug resistance2|1881|0更新时间：2025-12-31
- 摘要：Background and purpose: Internal mammary lymph node (IMLN) has a similar predictive value of distant metastasis and long-term recurrence as that of axillary lymph node. IMLN can not be removed under modified radical mastectomy, so the blind radiotherapy can sometimes be applied to the patients with suspected metastasis in the internal mammary region clinically. How to select the breast cancer patients who are suitable for IMLN biopsy or resection is an urgent clinical problem. This study aimed to investigate the feasibility of internal mammary sentinel lymph node (SLN) mapping using magnetic resonance lymphography (MR-LG) in VX2 rabbit breast cancer model. Methods: Fifty-five purebred female New Zealand white rabbits were used to establish the model of VX2 rabbit breast cancer, then MR-LG examinations were performed. The raw images were transferred to Philips IntelliSpace Portal (ISP) workstation for post-processing. The first one or several lymph nodes along the lymph duct draining from the injection sites to axilla or internal mammary were defined as SLN. The SLN and draining lymphatic vessels were recorded, then compared with the results of SLN biopsy (SLNB). Results: The success rate of model establishment was 98.2% (54/55), and 51 rabbits were enrolled in this study finally. On MR-LG, compared with the mapping of SLN and lymph ducts immediately after administration of the contrast agent, more internal mammary lymph ducts (36 vs 25, P=0.021) were shown, and more rabbits with both axillary SLN and lymph ducts mapping were detected (45 vs 37, P= 0.040) 5 minutes after administration of the contrast agent. On the internal mammary MR-LG, the long diameter, the short diameter of SLN and the diameter of mapping lymph ducts were (2.64±0.59) mm, (2.24±0.54) mm and 2.18 mm, respectively. The size of tumor and the number of axillary lymph nodes had significantly different effects on the mapping of internal mammary lymph ducts (P=0.032 and 0.040, respectively). Among 15 internal mammary SLNs detected on 11 cancer-bearing rabbits by SLNB, 6 SLNs were located at the 2nd and the 3rd intercostal space, 5 SLNs at the 1st and the 2nd intercostal space, 2 SLNs at the 3rd and the 4th intercostal space, and one SLN at the 10th intercostal space and xiphoid process. On MR-LG, 11 SLNs were detected in 9 cancer-bearing rabbits, and 7 rabbits (77.8%, 7/9) showed the same results on SLNB. Both the long and short diameters of SLNs measured by SLNB were bigger than those of SLNs measured by MR-LG, which showed significant differences (both P<0.05). Conclusion: MR-LG can be used for mapping internal mammary SLN of VX2 rabbit breast cancer. However, the mapping rate should be improved by further study.关键词：VX2 rabbit breast cancer;Internal mammary lymph node;Sentinel lymph node;MR lymphography2|1789|0更新时间：2025-12-31
- 摘要：Background and purpose: Basal cell adenoma (BCA) of the parotid gland has low incidence and high misdiagnosis rate in clinical practice. So far, the report on the MRI manifestation of BCA is rare. Our study combined dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) with diffusion weighed imaging (DWI) to investigate the MRI features of BCA of the parotid gland and its correlation with pathologic features. Methods: We retrospectively analyzed the correlation of MRI findings and pathology in 26 patients with histopathologically proven BCA of the parotid gland. The clinical presentation, pathologic features and localization, size, number, shape, signal, enhancement pattern of tumor were analyzed. Results: In this study, 18 patients (69.2%) were female and 8 patients (30.8%) were male. The median age was 51 (range 32-72) years. Twenty-five patients (96.2%) had single lesion and only one patient (3.8%) had two. The average size of the 27 lesions was 22 (range 11-36) mm. Thirteen lesions were located in superficial lobe, 5 in deep lobe and 9 across both lobes. All the 27 lesions had clear margin without lobular appearance and 25 lesions had complete or incomplete hypo-intensity rim in T2WI. Compared with neck muscle, all 27 lesions showed iso- or hyper-intense in T1WI and hyper-intense in T2WI. Twenty-one lesions (77.8%) had cystic change with varying size. The signal intensities of solid part of lesions were homogeneous in 21 lesions, heterogeneous in 6. Twenty-one lesions (77.8%) showed persistent enhancement and 6 (22.2%) had outflow enhancement. DWI was performed in 9 patients (10 lesions), the mean ADC value was (1.22±0.20)×10-3 mm2/s. Under microscope, it consisted of a monomorphic population of basaloid epithelial cells, organized with prominent basal cell layer and distinct basement membrane-like material, lacking the myxochondroid stromal component. Conclusion: BCA of the parotid gland has certain clinical and MRI features. Analysis of the correlation between the MRI findings and the pathologic features may be helpful in making qualitative and differential diagnosis of BCA.关键词：Parotid gland;Basal cell adenoma;Magnetic resonance imaging;Pathology2|2752|0更新时间：2025-12-31
- 摘要：Background and purpose: Contrast-enhanced spectral mammography (CESM) is a new technology introduced in recent years, and a technique based on conventional mammography. The radiation dose of the CESM was analyzed by comparing the average gland dose (AGD) of the low energy imaging and the CESM. Methods: A total of 143 patients with clinically palpable breast masses were enrolled in this study. The AGD of the two imaging methods were analyzed according to the type of breast glands (7 cases of almost entirely fatty type, 31 cases of scattered areas of fibroglandular density type, 76 cases of heterogeneously dense type, 29 cases of extremely dense type), lesion site (70 cases of right breast mass, 64 cases of left breast mass, 9 cases of bilateral breast mass) and age distribution (<40 years in 27 cases, 41-50 years in 51 cases, 51-60 years in 50 cases, 61-70 years old in 15 cases). Results: The AGD of CESM of all the 143 patients was higher (26.22% ) than that of low energy imaging (P<0.05). The AGD of the four gland types of a, b, c and d in the CESM group were higher than those in the low energy imaging group by 26.05%, 25.92%, 26.82% and 24.93% respectively. Therefore the AGD of c-type gland increased the most, whereas AGD of d-type gland increased the least (P<0.05). The AGD of the affected side breast (4.15%) was higher than that of the unaffected side breast (P<0.05). There were statistically significant differences between the two groups by age (41-50 years, 51-60 years) (P<0.05). Conclusion: Radiation dose of CESM is slightly higher than that of low energy imaging in general and differences by breast gland types, lesion site and age can be observed. However, CESM is still a safe and reliable diagnostic imaging technology and can be applied according to clinical needs.关键词：Contrast-enhanced spectral mammography;Full field digital mammography;Average gland dose;Radiation dosage2|2630|0更新时间：2025-12-31
- 摘要：Background and purpose: The effect of minimal extrathyroid invasion (MEI) on mortality in differentiated thyroid cancer (DTC) patients was eliminated from the 8th TNM staging system. This study aimed to analyze the correlation between MEI and recurrence risk in DTC patients. Methods: We retrospectively analyzed 942 DTC patients without distant metastasis who were treated in Peking Union Medical College Hospital with a median follow-up of 24 months. Patients were divided into two groups: disease recurrence/persistence patients as structural incomplete response group (SIR, n=55), and non-SIR as NSIR group (n=887) according to their response to therapy. Chi-square test and rank-sum test were used to evaluate the statistical differences in basic clinicopathologic features between two groups. Multivariate analysis was used to quantify the influence factors for SIR. Correlation analysis was conducted between MEI and recurrence. We compared the clinical-pathologic features and responses between low-risk group (G1, n=39) and minimal extrathyroid invasion group (G2, no other risk factors, n=65). Result: There were statistical differences in tumor size (P=0.018), lymph node stage (P=0.008) and macroscopic extrathyroid invasion (P=0.008) between SIR group and NSIR group, and no significant difference in MEI (P=0.444) between the groups. Tumor size (P=0.007) and macroscopic extrathyroid invasion (P=0.036) were two independent influence factors for SIR in multivariate analysis. It showed no correlation between MEI and SIR (r=-0.026, P=0.425). G2 showed a high rate of female (P=0.018) and age at diagnosis (P=0.033) compared with G1. There was no significant difference in tumor size (P=0.517), tumor multifocality (P=1.000) and dose of 131I (P=1.000 ), as well as the recurrence between G1 and G2 (1.5% vs 2.6%, P=0.244). Conclusion: MEI should not be an independent risk factor for recurrence in DTC patients.关键词：Differentiated thyroid cancer;131I therapy;Minimal extrathyroid invasion;Recurrence;Response2|3270|0更新时间：2025-12-31
- 摘要：Background and purpose: It was controversial that value of the first pre-ablation stimulated thyroglobulin (sTg) in the diagnosis of recurrence or metastasis of differentiated thyroid carcinoma (DTC), due to the influence of many factors such as residual thyroid. In this study, we investigated the significance of the first pre-ablation sTg in predicting neck and distant metastasis in postoperative patients with DTC. Methods: The study included 106 patients with DTC who had undergone total thyroidectomy and lymphadenectomy. The pre-ablation sTg of 106 patients was measured one day before the first 131I ablation therapy, and the patients underwent 131I whole-body imaging and SPECT/CT fusion imaging 5-7 days after 131I ablation therapy. Patients were divided into 3 groups as M0 group, M1 group and M2 group according to the presence and absence of metastases, respectively. The sTg values between groups were compared by Mann-Whitney rank-sum test. The ROC curves and diagnostic critical point (DCP) were analyzed to evaluate the predictive value of sTg. Results: The pre-ablation sTg of M1 group and M2 group were significantly higher than that of M0 group (U=143.00, P<0.01; U=60.00, P<0.01). Areas under the ROC curve for sTg were 0.872 and 0.964, respectively. The cut-off values of DCP of sTg were 23.95 ng/mL with a sensitivity of 68.42%, specificity of 100%, accuracy of 92.31%, and 20.93 ng/mL with a sensitivity of 85.71%, specificity of 100%, accuracy of 95.40%, respectively. Conclusion: The pre-ablation sTg value may be a useful diagnostic marker for predicting metastasis before the first 131I ablation therapy, especially for the prediction of distant metastasis.关键词：Differentiated thyroid carcinoma;Thyroglobulin;Radioiodine therapy2|2392|0更新时间：2025-12-31
- 摘要：Background andpurpose: The majority of recurrent hepatocellular carcinoma (HCC) is small nodule with less than 3 cm in diameter, and the treatment of radiofrequency ablation (RFA) is associated with a prolonging survival time in patients with small HCC. This study aimed to explore the efficacy and safety of RFA for recurrent HCC. Methods: The 1-, 3- and 5-year overall survival (OS) rate and progression-free survival (PFS) rate of 61 patients with recurrent HCC undergoing transcatheter arterial chemoembolization (TACE) and RFA after hepatectomy were retrospectively evaluated by the Kaplan-Meier method. Furthermore, the complication rate, mortality rate and prognostic factor for OS were evaluated in this study. Results: The 1-, 3-, and 5-year OS rates were 96.3%, 77.9% and 77.9%, respectively. The 1-, 3-, and 5-year PFS rates were 48.6%, 20.3% and 13.5%, respectively. Fifty-seven patients (93.4%) achieved complete ablation. There was one patient with a major complication, and no death case due to RFA was found. The median length of hospitalization was 5 days (quartile, 4-7). The prognostic factor for OS was the expression of HBsAg (P=0.044, HR=7.496, 95%CI: 1.057-53.152). Conclusion: RFA was a safe and effective treatment modality for recurrent HCC after hepatectomy.关键词：肝细胞癌;复发;射频消融2|1927|0更新时间：2025-12-31
- 摘要：Background and purpose: Hepatitis B virus (HBV) reactivation is one of the serious complications among patients with acute myeloid leukemia (AML) following cytotoxic induction and consolidation chemotherapy. Nucleoside analogs including lamivudine and entecavir have been widely used as prophylactic or preemptive treatment for HBV reactivation. This study was to investigate clinical efficacy and safety of long or short course oral anti- HBV agents for preventing HBV reactivation in AML patients with HBV infection during chemotherapy. Methods: The medical records of 29 AML patients with HBV infection receiving at least 4 courses of chemotherapy were retrospectively identified and systematically analyzed. These patients were further divided into four groups according to their hepatitis B surface antigen (HBsAg) status prior to initiation of chemotherapy and duration of prophylactic therapy. Reactivation of HBV and toxicity profiles of oral antiviral agents were systematically analyzed and compared among different groups. Results: HBV reactivation and documented HBV-related hepatitis were significantly lower in AML patients under long course antiviral prophylaxis (i.e. continuing oral antiviral therapy for at least 6 months after cessation of chemotherapy, LCP group) than in the patients with short course antiviral prophylaxis (i.e. continuing oral antiviral therapy for one month after cessation of chemotherapy, SCP group), which was 5.56% (1/18) and 0% (0/18) compared with 45.45% (5/11) and 36.36% (4/11) (P=0.018 and P=0.014). There was little difference in the incidence of antiviral resistance between LCP and SCP groups ［11.11% (2/18) vs 9.09% (1/11), P>0.05］. Furthermore, the rates of HBV reactivation and HBV-related hepatitis were significantly lower in AML patients with positive HBsAg (HBsAg≥0.05 IU/mL) under long course antiviral prophylaxis than in HBsAg positive patients who received short course antiviral agents ［8.33% (1/12) and 0% (0/12) vs 66.67% (4/6) and 66.67% (4/6), P=0.022 and P=0.005］. Meanwhile, there was little difference in the rates of antiviral resistance between LCP and SCP groups among HBsAg positive patients ［8.33% (1/12) vs 16.67% (1/6), P>0.05］. In addition, the rates of HBV reactivation and HBV-related hepatitis as well as antiviral resistance were shown to have little difference in AML patients with negative HBsAg (HBsAg<0.05 IU/mL) between LCP and SCP groups. Concerning antiviral agent toxicity, no grade 3-4 toxicity occurred in patients from LCP or SCP group. Conclusion: Long course prophylaxis with oral antiviral agent appears to be an effective and well tolerated preventative approach for reducing risks of HBV reactivation and associated events in AML patients with positive HBsAg during chemotherapy, which serves as a platform for the design of prospective clinical trials.关键词：Acute myeloid leukemia;Hepatitis B virus reactivation;Prophylactic antiviral therapy2|1742|0更新时间：2025-12-31
- 摘要：Background and purpose: CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) is the standard chemotherapy regimen for aggressive non-Hodgkin lymphoma (NHL), which has a 10%-20% rate of febrile neutropenia (FN). Recently, pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) is frequently used in clinical practice. Our study aimed to investigate the efficacy and safety of prophylactic PEG-rhG-CSF in patients with non-Hodgkin lymphoma on CHOP-based chemotherapy. Methods: In this study, we retrospectively analyzed the clinical data of 75 patients. of whom 36 received primary prophylaxis, 39 received secondary prophylaxis. All patients completed their treatment and were included in data analysis. Results: In primary prophylaxis group, 52.8% patients did not have grade 4 or FN and 63.9% completed their treatment without dose reduction. In secondary prophylaxis group, 61.5% patients did not have grade 4 or FN and 66.7% completed their treatment without dose reduction. Multivariate analysis showed that old age (≥65 years) and stage 3/4 were independent factors for serious neutropenia and dose reduction. In regard to the safety profiles, transient grade 1-2 lumbosacral pain was the main adverse effect. Conclusion: Prophylactic use of PEG-rhG-CSF is not only convenient but also efficacious and well tolerated. Therefore, its routine clinical application is recommended.关键词：Pegylated recombinant human granulocyte colony stimulating factor;Non-Hodgkin's lymphoma;CHOP;Neutropenia;Febrile neutropenia2|2287|0更新时间：2025-12-31
- 摘要：Background and purpose: At present, the published articles have indicated that pulmonary nodule surgery positioning is mainly focused on the CT-guided preoperative localization. This study aimed to explore a simpler, safe and reliable method of lung nodule localization, in order to provide precise positioning of pulmonary nodules for thoracoscopic lung resection. Methods: Fifty-six patients with small pulmonary nodules received CT scanning to find the position of the small nodules on the chest wall before partial lung resection. Venous catheter was used in the preoperative location points. We exhorted the anesthesiologist to do the lung inflation. The positioning point of the lung surface was left using the electric coagulation for the metal inner core of casing needle. The location of the nodule was confirmed by the electric coagulation and burning point. We counted location accuracy rate, complication rate, video-assisted thoracic surgery (VATS) success rate of pulmonary resection. Results: The data of the distance between pulmonary nodules anchor point and nodules of the surface location method on the chest wall were collected. Finally, the operation success rate was 94.6%. The small nodules in 3 cases were found to have a significant deviation (>1.5 cm) from the positioning points. There were 2 cases with active bleeding (3.6%), no other complications occurred. Conclusion: In contrast to other preoperative localization methods (such as hookwire), intraoperative localization of lung nodules on the body surface during operation can protect patients from prolonged exposure to radiation, reduce pain and psychological burden of patients, reduce the steps of preoperative localization. Intraoperative immediate operation could avoid other complications of invasive location method. It is a simple, safe, economical and accurate method for the preoperative localization of pulmonary nodules.关键词：Small pulmonary nodules;Body surface localization;Thoracoscopy2|3936|0更新时间：2025-12-31
- 摘要：Background and purpose: Retroperitoneal sarcoma is a rare kind of malignant neoplasms. Complete resection plays a key role in the treatment of retroperitoneal sarcoma, but the recurrence rate is high. Most of the patients with recurrent retroperitoneal sarcoma were eventually diagnosed by a follow-up examination. Again a hard surgical resection with bleeding profusely was approached because of its unclear anatomical level. In this study, we investigated the clinical features, treatment modalities and prognosis of patients with recurrent retroperitoneal sarcoma. Methods: Twenty-five patients with recurrent retroperitoneal sarcomas admitted from Oct. 2007 to Oct. 2016 for surgical resection in a single institution were divided into the complete resection group and partial excision and biopsy group after the operation. Statistical analysis was done using the univariate logistic regression analysis. The survival rate was calculated using Kaplan-Meier curve. Results: A total of 25 cases were enrolled in this study. Grossly complete resection was performed in 16 cases (complete excision rate was 64.0%). Partial excision and biopsy were performed in 6 (24.0%) and 3 (12.0%) cases respectively. Among 16 patients who underwent complete gross resection, 8 had concomitant resection of adjacent viscera (50%). Twenty-four cases had full followup data. The 5-year survival rates of complete resection and partial resection were 56.3% (9/16) and 20% (1/5). The differences between the two groups were significant (P<0.05). Conclusion: Complete resection plays an important role in the treatment for recurrent retroperitoneal sarcoma. The study demonstrates that concomitant resection of the adjacent viscera can improve the rate of complete gross resection. Because of the high recurrence rate in malignant tumors, long-term follow-up care is needed.关键词：Retroperitoneal sarcoma;Resection;Prognosis2|2609|0更新时间：2025-12-31
- 摘要：Background and purpose: DWI is an ideal way to check the diffusion of water molecules in vivo. Apparent diffusion coefficient value derived from DWI based on a mono-exponential model does not sufficiently demonstrate the characteristics of tissue behavior. Intravoxel incoherent motion (IVIM) can be used to estimate molecular diffusion and microcirculation in the capillaries separately through bi-exponential fitting of the DWI data using low and high b-value. This study aimed to determine the value of IVIM in predicting treatment response before preoperative chemoradiotherapy in locally advanced rectal cancer. Methods: A cohort of consecutive patients with histologically confirmed rectal adenocarcinoma treated with preoperative chemoradiotherapy followed by total mesorectal excision (TME) surgery was enrolled in a prospective pilot trial. All patients were examined using IVIM at two time points: 2 to 5 days before neoadjuvant chemoradiotherapy, 1 to 4 days before surgery. The perfusion parameters (ADCstandard, D, D*, f) were measured for tumor. The patients were classified into pathological complete response (pCR) group and non-pCR group according to the pathological results after operation. Those diffusion parameters were compared between before and after neoadjuvant chemoradiotherapy in all patients as well as in pCR and non-pCR groups with the t-test. Results: The final study population consisted of 32 patients. There were 11 patients with pCR and 21 patients with non-pCR. The mean tumor ADCstandard using the mono-exponential model for all patients was (133.2±21.5)×10-5 mm/s before neoadjuvant chemoradiotherapy, (166.9±29.7)×10-5 mm/ s after neoadjuvant chemoradiotherapy. The parameters showed significant difference between those two groups. By using the bi-exponential DWI in this study, we found that the mean tumor D* was (4 471±1 271)×10-5 mm/s for pCR group, (5 749±1 722)×10-5 mm/s for non-pCR group before neoadjuvant chemoradiotherapy. After neoadjuvant chemoradiotherapy, the mean tumor D was (97.0±14.6)×10-5 mm/s for pCR group, (113.4±22.6)×10-5 mm/ s for nonpCR group. All the parameters showed significant differences between those two groups (all P<0.05). Conclusion: In locally advanced rectal cancer, IVIM of bi-exponential DWI can aid in describing diffusion information of tumor.关键词：Rectal cancer;Neoadjuvant chemoradiotherapy;Intravoxel incoherent motion2|1847|0更新时间：2025-12-31
- 摘要：Cancer is an important disease which jeopardizes people's health, and also one of the important causes of human death. With the progress of technology, the treatments of cancer are no longer limited to the surgical treatment, chemotherapy and traditional radiotherapy. Endocrine therapy, immunotherapy, targeted therapy and other novel therapeutic methods have also been developed. Although there are many therapies for cancer, the effect of cancer treatment is unsatisfactory. Poor therapeutic effect of cancer treatment is associated with difficulty of early diagnosis, deficiency of remedy and some other factors. Moreover, the emergence of resistance to the tumor treatment has also brought great obstacles to cancer therapy. In recent years, many studies have shown that there is a close relationship between high mobility group protein B1 (HMGB1) and tumor chemotherapy resistance. Some researchers have found that HMGB1 can promote tumor therapy resistance by participating in cell autophagy, DNA damage repair, resistance to cell apoptosis, promotion of cell proliferation and angiogenesis, enhancement of immune escape and inflammation. In this paper, the recent research progress of the correlation between HMGB1 and tumor therapy resistance were reviewed.关键词：HMGB1;Neoplasm;Therapy resistance2|2101|0更新时间：2025-12-31
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
0